Quick Answer
Protara Therapeutics, Inc. reported Total Revenue of $2.95 million for fiscal year 2014.
Protara Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$57.44M -28.8% |
-$44.60M -10.3% |
-$40.42M +38.7% |
-$65.95M -39.6% |
-$47.25M -39.1% |
-$33.98M -333.9% |
| Diluted EPS | -$1.34 +38.2% |
-$2.17 +39.2% |
-$3.57 +39.1% |
-$5.86 -39.2% |
-$4.21 | — |
| Total Assets | $209.47M +15.4% |
$181.45M +129.8% |
$78.95M -30.3% |
$113.29M -34.4% |
$172.60M -15.0% |
$203.16M +16511.4% |
| Cash and Equivalents | $49.66M -69.5% |
$162.80M +311.3% |
$39.59M +64.1% |
$24.13M -32.5% |
$35.72M -78.8% |
$168.60M +29793.3% |
| Stockholders Equity | $196.41M +17.5% |
$167.13M +144.6% |
$68.32M -33.1% |
$102.08M -37.0% |
$161.91M -18.7% |
$199.24M +9462.9% |
| R&D Expense | $42.63M +34.5% |
$31.70M +26.9% |
$24.99M +48.7% |
$16.81M -20.3% |
$21.09M +76.0% |
$11.98M +209.0% |
| Operating Income | -$64.55M -31.3% |
-$49.15M -12.7% |
-$43.61M +35.0% |
-$67.06M -41.2% |
-$47.49M -37.9% |
-$34.44M -339.9% |
| Shares Outstanding | 53.59M +52.9% |
35.04M +208.4% |
11.36M +0.9% |
11.27M +0.3% |
11.24M +0.2% |
11.21M +326.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2014 | $2.95M | — | — |
| Net Income | September 30, 2025 | -$13.26M | -18.2% | +11.4% |
| Diluted EPS | September 30, 2025 | -$0.31 | +38.0% | +11.4% |
| Total Assets | September 30, 2025 | $144.64M | +53.7% | -7.8% |
| Cash and Equivalents | September 30, 2025 | $12.55M | -75.8% | -60.2% |
| Stockholders Equity | September 30, 2025 | $132.29M | +61.7% | -8.4% |
| R&D Expense | September 30, 2025 | $9.59M | +18.8% | -10.9% |
| Operating Income | September 30, 2025 | -$14.76M | -19.7% | +11.0% |
| Shares Outstanding | September 30, 2025 | 38.59M | +87.0% | +0.0% |
- Protara Therapeutics, Inc. reported Total Revenue of $2.95 million for fiscal year 2014.
- Protara Therapeutics, Inc. reported Net Income of -$57.44 million for fiscal year 2025.
- Protara Therapeutics, Inc. showed a decrease of -28.8% in Net Income compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported Diluted EPS of $1.34 per share (loss) for fiscal year 2025.
- Protara Therapeutics, Inc. showed an increase of +38.2% in Diluted EPS compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported Total Assets of $209.47 million for fiscal year 2025.
- Protara Therapeutics, Inc. showed an increase of +15.4% in Total Assets compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported Cash and Equivalents of $49.66 million for fiscal year 2025.
- Protara Therapeutics, Inc. showed a decrease of -69.5% in Cash and Equivalents compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported Stockholders Equity of $196.41 million for fiscal year 2025.
- Protara Therapeutics, Inc. showed an increase of +17.5% in Stockholders Equity compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported R&D Expense of $42.63 million for fiscal year 2025.
- Protara Therapeutics, Inc. showed an increase of +34.5% in R&D Expense compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported Operating Income of -$64.55 million for fiscal year 2025.
- Protara Therapeutics, Inc. showed a decrease of -31.3% in Operating Income compared to the prior fiscal year.
- Protara Therapeutics, Inc. reported Shares Outstanding of 53.59 million shares for fiscal year 2025.
- Protara Therapeutics, Inc. showed an increase of +52.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: